140 related articles for article (PubMed ID: 25873360)
1. How do patients with uveal melanoma experience and manage uncertainty? A qualitative study.
Hope-Stone L; Brown SL; Heimann H; Damato B; Salmon P
Psychooncology; 2015 Nov; 24(11):1485-91. PubMed ID: 25873360
[TBL] [Abstract][Full Text] [Related]
2. Is accurate routine cancer prognostication psychologically harmful? 5-year outcomes of life expectancy prognostication in uveal melanoma survivors.
Brown SL; Fisher P; Hope-Stone L; Damato B; Heimann H; Hussain R; Cherry MG
J Cancer Surviv; 2022 Apr; 16(2):408-420. PubMed ID: 33871760
[TBL] [Abstract][Full Text] [Related]
3. 'I Don't Like Uncertainty, I Like to Know': How and why uveal melanoma patients consent to life expectancy prognostication.
Brown SL; Fisher PL; Morgan A; Davies C; Olabi Y; Hope-Stone L; Heimann H; Hussain R; Cherry MG
Health Expect; 2022 Aug; 25(4):1498-1507. PubMed ID: 35474381
[TBL] [Abstract][Full Text] [Related]
4. Psychological aspects of cytogenetic testing of uveal melanoma: preliminary findings and directions for future research.
Cook SA; Damato B; Marshall E; Salmon P
Eye (Lond); 2009 Mar; 23(3):581-5. PubMed ID: 18344957
[TBL] [Abstract][Full Text] [Related]
5. Psychosocial impact of prognostic genetic testing in the care of uveal melanoma patients: protocol of a controlled prospective clinical observational study.
Erim Y; Scheel J; Breidenstein A; Metz CH; Lohmann D; Friederich HC; Tagay S
BMC Cancer; 2016 Jul; 16():408. PubMed ID: 27386847
[TBL] [Abstract][Full Text] [Related]
6. Depression, Anxiety, and Regret Before and After Testing to Estimate Uveal Melanoma Prognosis.
Schuermeyer I; Maican A; Sharp R; Bena J; Triozzi PL; Singh AD
JAMA Ophthalmol; 2016 Jan; 134(1):51-6. PubMed ID: 26539659
[TBL] [Abstract][Full Text] [Related]
7. Long-term uveal melanoma survivors: measuring their quality of life.
Frenkel S; Rosenne H; Briscoe D; Hendler K; Bereket R; Molcho M; Pe'er J
Acta Ophthalmol; 2018 Jun; 96(4):e421-e426. PubMed ID: 29369538
[TBL] [Abstract][Full Text] [Related]
8. Psychosocial impact of prognostic genetic testing in uveal melanoma patients: a controlled prospective clinical observational study.
Lieb M; Tagay S; Breidenstein A; Hepp T; Le Guin CHD; Scheel J; Lohmann DR; Bornfeld N; Teufel M; Erim Y
BMC Psychol; 2020 Jan; 8(1):8. PubMed ID: 32005293
[TBL] [Abstract][Full Text] [Related]
9. What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life.
Ng CA; Luckett T; Mulhern B; Kee D; Lai-Kwon J; Joshua AM
Melanoma Res; 2024 Jun; 34(3):248-257. PubMed ID: 38469755
[TBL] [Abstract][Full Text] [Related]
10. Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study.
Brandberg Y; Kock E; Oskar K; af Trampe E; Seregard S
Eye (Lond); 2000 Dec; 14(Pt 6):839-46. PubMed ID: 11584839
[TBL] [Abstract][Full Text] [Related]
11. The use of semistructured interviews to assess quality of life impacts for patients with uveal melanoma.
Kopp BC; Crump RT; Weis E
Can J Ophthalmol; 2017 Apr; 52(2):181-185. PubMed ID: 28457288
[TBL] [Abstract][Full Text] [Related]
12. Uncertainty and control in the context of a category-five tornado.
Afifi WA; Afifi TD; Merrill A
Res Nurs Health; 2014 Oct; 37(5):358-66. PubMed ID: 25163986
[TBL] [Abstract][Full Text] [Related]
13. A qualitative assessment of psychosocial impact, coping and adjustment in high-risk melanoma patients and caregivers.
Tan JD; Butow PN; Boyle FM; Saw RP; O'Reilly AJ
Melanoma Res; 2014 Jun; 24(3):252-60. PubMed ID: 24584097
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in the follow-up of uveal melanoma patients after CyberKnife treatment.
Klingenstein A; Fürweger C; Nentwich MM; Schaller UC; Foerster PI; Wowra B; Muacevic A; Eibl KH
Melanoma Res; 2013 Dec; 23(6):481-8. PubMed ID: 24048223
[TBL] [Abstract][Full Text] [Related]
15. Two-year patient-reported outcomes following treatment of uveal melanoma.
Hope-Stone L; Brown SL; Heimann H; Damato B; Salmon P
Eye (Lond); 2016 Dec; 30(12):1598-1605. PubMed ID: 27589051
[TBL] [Abstract][Full Text] [Related]
16. When the risks are high: psychological adjustment among melanoma survivors at high risk of developing new primary disease.
McLoone J; Watts K; Menzies S; Meiser B; Butow P; Kasparian N
Qual Health Res; 2012 Aug; 22(8):1102-13. PubMed ID: 22673092
[TBL] [Abstract][Full Text] [Related]
17. Confronting the unexpected: temporal, situational, and attributive dimensions of distressing symptom experience for breast cancer survivors.
Rosedale M; Fu MR
Oncol Nurs Forum; 2010 Jan; 37(1):E28-33. PubMed ID: 20044329
[TBL] [Abstract][Full Text] [Related]
18. [Cured after an intraocular tumor].
Desjardins L; Delage M; Lumbroso L; Levy C; Doz F
Bull Cancer; 2001 Nov; 88(11):1069-74. PubMed ID: 11741800
[TBL] [Abstract][Full Text] [Related]
19. Depression and quality of life during treatment of ocular bulb removal in individuals with uveal melanoma.
Amaro TA; Yazigi L; Erwenne C
Eur J Cancer Care (Engl); 2010 Jul; 19(4):476-81. PubMed ID: 19912303
[TBL] [Abstract][Full Text] [Related]
20. Predictors of anxiety and depression 2 years following treatment in uveal melanoma survivors.
Brown SL; Hope-Stone L; Heimann H; Damato B; Salmon P
Psychooncology; 2018 Jul; 27(7):1727-1734. PubMed ID: 29601654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]